CN110062757A - 凝血因子XIa抑制剂及其用途 - Google Patents

凝血因子XIa抑制剂及其用途 Download PDF

Info

Publication number
CN110062757A
CN110062757A CN201880004854.3A CN201880004854A CN110062757A CN 110062757 A CN110062757 A CN 110062757A CN 201880004854 A CN201880004854 A CN 201880004854A CN 110062757 A CN110062757 A CN 110062757A
Authority
CN
China
Prior art keywords
alkyl
independently
compound
former molecular
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004854.3A
Other languages
English (en)
Other versions
CN110062757B (zh
Inventor
左应林
王建成
林继华
张英勋
曹生田
吴方园
杨雯
许娟
王晓军
张英俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN110062757A publication Critical patent/CN110062757A/zh
Application granted granted Critical
Publication of CN110062757B publication Critical patent/CN110062757B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

提供一类具有抑制凝血因子XIa和/或血浆激肽释放酶活性的大环化合物及其药物组合物；其中，所述大环化合物及其药物组合物可用于治疗或预防血栓栓塞性疾病。

Description

PCT国内申请，说明书已公开。

Claims (32)

  1. PCT国内申请，权利要求书已公开。
CN201880004854.3A 2017-01-18 2018-01-17 凝血因子XIa抑制剂及其用途 Active CN110062757B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710036621 2017-01-18
CN2017100366219 2017-01-18
PCT/CN2018/072988 WO2018133793A1 (zh) 2017-01-18 2018-01-17 凝血因子XIa抑制剂及其用途

Publications (2)

Publication Number Publication Date
CN110062757A true CN110062757A (zh) 2019-07-26
CN110062757B CN110062757B (zh) 2022-03-04

Family

ID=62908170

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004854.3A Active CN110062757B (zh) 2017-01-18 2018-01-17 凝血因子XIa抑制剂及其用途

Country Status (2)

Country Link
CN (1) CN110062757B (zh)
WO (1) WO2018133793A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020272973A1 (en) * 2019-04-11 2021-12-02 Bristol-Myers Squibb Company Novel synthetic options towards the manufacture of (6R,10S)-10- {4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6H)-one
KR20220002966A (ko) 2019-04-16 2022-01-07 메드샤인 디스커버리 아이엔씨. XIa 인자 억제제로서의 거대고리 유도체
WO2021013209A1 (zh) 2019-07-23 2021-01-28 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
WO2021121396A1 (zh) * 2019-12-20 2021-06-24 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途
WO2021136390A1 (zh) * 2019-12-31 2021-07-08 上海京新生物医药有限公司 凝血因子XIa抑制剂
TW202246268A (zh) * 2021-04-21 2022-12-01 大陸商上海美悦生物科技發展有限公司 FXIa抑制劑及其藥物組合物、製備方法和用途
CN114984820B (zh) * 2022-05-27 2023-09-29 吉林大学 一种采血管晃动式达到血液混合的摇匀台

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507924A (zh) * 2012-08-03 2015-04-08 百时美施贵宝公司 二氢吡啶酮p1作为凝血因子xia抑制剂
CN104520289A (zh) * 2012-08-03 2015-04-15 百时美施贵宝公司 作为凝血因子xia抑制剂的二氢吡啶酮p1
CN105980384A (zh) * 2014-01-31 2016-09-28 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2＇基团的大环化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
NO2760821T3 (zh) * 2014-01-31 2018-03-10
NO2721243T3 (zh) * 2014-10-01 2018-10-20

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104507924A (zh) * 2012-08-03 2015-04-08 百时美施贵宝公司 二氢吡啶酮p1作为凝血因子xia抑制剂
CN104520289A (zh) * 2012-08-03 2015-04-15 百时美施贵宝公司 作为凝血因子xia抑制剂的二氢吡啶酮p1
CN105980384A (zh) * 2014-01-31 2016-09-28 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2＇基团的大环化合物

Also Published As

Publication number Publication date
WO2018133793A1 (zh) 2018-07-26
CN110062757B (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
CN110062757A (zh) 凝血因子XIa抑制剂及其用途
TWI787018B (zh) 轉染過程重排之抑制劑
CN105085489B (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
CN104945395B (zh) 二氢嘧啶类化合物及其在药物中的应用
CN108473502A (zh) 用于治疗癌症的4,6二氢吡咯并[3,4-c]吡唑-5(1h)-腈衍生物
CN110256421A (zh) Kras-g12c抑制剂
CN102906092A (zh) 某些三唑并吡啶化合物和三唑并吡嗪化合物、其组合物和其使用方法
CN104650069B (zh) 4-甲基二氢嘧啶类化合物及其在药物中的应用
CN107072985A (zh) 治疗性抑制化合物
EP3484881A1 (en) Bicyclic heteroaryl substituted compounds
CN105541693B (zh) 芳杂环类衍生物及其在药物上的应用
CN107001340A (zh) 二杂芳基组蛋白脱乙酰基酶抑制剂及其治疗用途
CN107001333A (zh) 多杂芳基组蛋白脱乙酰基酶抑制剂及其治疗用途
EP3484874B1 (en) Monocyclic heteroaryl substituted compounds
CN104804017B (zh) 噁唑烷酮类化合物及其在药物中的应用
CN110312717A (zh) 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
CN105367582B (zh) 银杏内酯b衍生物及其在药物中的应用
CN105377848A (zh) 取代的三唑并吡啶的前体药物衍生物
CN108069952A (zh) 喹啉酮类化合物及其在药物中应用
KR20240004634A (ko) 삼환식 유비퀴틴 특이적 프로테아제 1 억제제 및 이의 용도
EP4294798A1 (en) Factor xiia inhibitors
CN104530046B (zh) 二氮杂螺类化合物及其在药物中的应用
TWI749881B (zh) 二氧代哌類衍生物、其製備方法及其在醫藥上的應用
CN108069957A (zh) 脯氨酰羟化酶抑制剂及其用途
CN104447728B (zh) 噁唑烷酮类化合物及其在药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.